Elevated levels of serum neurofilament-light chain (NfL), a marker of axonal damage, are an indicator of increased microglial activation in the brain, according to a positron emission tomography (PET) study in Finland (Saraste et al. J Neurol Neurosurg Psychiatry 2023;94:698-706). Read More
Latest News
Biomarkers after stopping treatment may identify at-risk MS patients
November 30, 2023Increasing levels of neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) after drug discontinuation may identify previously stable MS patients at risk of new disease activity, according to Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) investigators (Bose et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200167; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC10574823/pdf/NXI-2023-000383.pdf ). Read More
Exploring the lung-brain axis in MS
November 29, 2023An emerging concept in MS research is the role of the lung microbiome in promoting disease severity, with preliminary evidence showing that pulmonary micro-organisms can regulate autoimmunity in the central nervous system (reviewed in Chen et al. Int J Mol Sci 2023;24:2170). Read More
Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies
November 22, 2023Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides